Mechanism of astragaloside Ⅳ alleviating PC12 cell injury by activating PI3K/AKT signaling pathway: based on network pharmacology and in vitro experiments.
10.19540/j.cnki.cjcmm.20210902.702
- Author:
Tian-Qi ZHANG
1
;
Chuan-Cheng LI
2
;
Tie-Feng ZHANG
1
;
Ming-Yan WANG
3
;
Sai-Nan CUI
4
;
Qing HUO
5
Author Information
1. Shandong University of Traditional Chinese Medicine Ji'nan 250355, China.
2. Linyi Central Hospital Linyi 276400, China.
3. Guangrao County People's Hospital Dongying 257300, China.
4. Guangzhou University of Chinese Medicine Guangzhou 510006, China.
5. Shandong Affiliated Hospital of University of Traditional Chinese Medicine Ji'nan 250011, China.
- Publication Type:Journal Article
- Keywords:
PI3K/AKT signaling pathway;
astragaloside Ⅳ;
cell experiment;
molecular docking;
network pharmacology
- MeSH:
Animals;
Drugs, Chinese Herbal/pharmacology*;
Molecular Docking Simulation;
Network Pharmacology;
PC12 Cells;
Phosphatidylinositol 3-Kinases/genetics*;
Proto-Oncogene Proteins c-akt/genetics*;
Rats;
Saponins;
Signal Transduction;
Triterpenes
- From:
China Journal of Chinese Materia Medica
2021;46(24):6465-6473
- CountryChina
- Language:Chinese
-
Abstract:
In this study, the molecular mechanism of astragaloside Ⅳ(AS-Ⅳ) in the treatment of Parkinson's disease(PD) was explored based on network pharmacology, and the potential value of AS-Ⅳ in alleviating neuronal injury in PD by activating the PI3 K/AKT signaling pathway was verified through molecular docking and in vitro experiments. Such databases as SwissTargetPrediction, BTMAN-TAM, and GeneCards were used to predict the targets of AS-Ⅳ for the treatment of PD. The Search Tool for the Retrieval of Interacting Genes/Proteins(STRING) was employed to analyze protein-protein interaction(PPI) and construct a PPI network, and the Database for Annotation, Visualization and Integrated Discovery(DAVID) was used for Gene Ontology(GO) term enrichment and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis. Based on the results of GO enrichment analysis and KEGG pathway analysis, the PI3 K/AKT signaling pathway was selected for further molecular docking and in vitro experiments in this study. The in vitro cell model of PD was established by MPP~+. The cell viability was measured by MTT assay and effect of AS-Ⅳ on the expression of the PI3 K/AKT signaling pathway-related genes and proteins by real-time polymerase chain reaction(RT-PCR) and Western blot. Network pharmacology revealed totally 122 targets of AS-Ⅳ for the treatment of PD, and GO enrichment analysis yielded 504 GO terms, most of which were biological processes and molecular functions. Totally 20 related signaling pathways were screened out by KEGG pathway analysis, including neuroactive ligand-receptor interaction, PI3 K/AKT signaling pathway, GABAergic synapse, and calcium signaling pathway. Molecular docking demonstrated high affinity of AS-Ⅳ to serine/threonine-protein kinases(AKT1, AKT2), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma(PIK3 CG), and phosphoinositide-3-kinase, catalytic, alpha polypeptide(PIK3 CA) on the PI3 K/AKT signaling pathway. In vitro experiments showed that AS-Ⅳ could effectively inhibit the decrease of the viability of PC12 induced by MPP~+ and up-regulate the mRNA expression levels of AKT1 and PI3 K as well as the phosphorylation levels of AKT and PI3 K. As an active component of Astragali Radix, AS-Ⅳ acts on PD through multiple targets and pathways. Furthermore, it inhibits neuronal apoptosis and protects neurons by activating the PI3 K/AKT signaling pathway, thereby providing reliable theoretical and experimental supports for the treatment of PD with AS-Ⅳ.
